Page 21 - 磁共振成像2024年7期电子刊

特别关注｜｜Special Focus 磁共振成像 2024年7月第15卷第7期 Chin J Magn Reson Imaging, Jul, 2024, Vol. 15, No. 7

s12987-018-0113-6. [35] NISHIZAWA S, INUBUSHI M, OKADA H. Physiological 18F-FDG
[15] GAUVAIN K, PONISIO M R, BARONE A, et al. F-FDOPA PET/ uptake in the ovaries and uterus of healthy female volunteers[J]. Eur J
18
MRI for monitoring early response to bevacizumab in children with Nucl Med Mol Imaging, 2005, 32(5): 549-556. DOI: 10.1007/
recurrent brain tumors[J]. Neurooncol Pract, 2018, 5(1): 28-36. DOI: s00259-004-1703-x.
10.1093/nop/npx008. [36] MENA E, BLACK P C, RAIS-BAHRAMI S, et al. Novel PET imaging
[16] GALLDIKS N, NIYAZI M, GROSU A L, et al. Contribution of PET methods for prostate cancer[J]. World J Urol, 2021, 39(3): 687-699.
imaging to radiotherapy planning and monitoring in glioma patients - a DOI: 10.1007/s00345-020-03344-3.
report of the PET/RANO group[J]. Neuro Oncol, 2021, 23(6): 881-893. [37] DARYANANI A, TURKBEY B. Recent advancements in CT and MR
DOI: 10.1093/neuonc/noab013. imaging of prostate cancer[J]. Semin Nucl Med, 2022, 52(3): 365-373.
[17] HIRATA K, YAMAGUCHI S, SHIGA T, et al. The roles of hypoxia DOI: 10.1053/j.semnuclmed.2021.11.013.
18
imaging using F-fluoromisonidazole positron emission tomography in [38] MANSBRIDGE M, CHUNG E, RHEE H. The use of MRI and PET
glioma treatment[J/OL]. J Clin Med, 2019, 8(8): 1088 [2024-03-05]. imaging studies for prostate cancer management: brief update, clinical
https://pubmed.ncbi.nlm.nih.gov/31344848/. DOI: 10.3390/jcm8081088. recommendations, and technological limitations[J/OL]. Med Sci, 2019,
[18] DUNET V, POMONI A, HOTTINGER A, et al. Performance of 7(8): 85 [2024-03-05]. https://pubmed.ncbi.nlm.nih.gov/31387208/. DOI:
18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain 10.3390/medsci7080085.
tumors: systematic review and meta-analysis[J]. Neuro-oncology, [39] FAROLFI A, CALDERONI L, MATTANA F, et al. Current and
2016, 18(3): 426-434. DOI: 10.1093/neuonc/nov148. emerging clinical applications of PSMA PET diagnostic imaging for
[19] DEUSCHL C, MOENNINGHOFF C, GOERICKE S, et al. Response prostate cancer[J]. J Nucl Med, 2021, 62(5): 596-604. DOI: 10.2967/
assessment of bevacizumab therapy in GBM with integrated jnumed.120.257238.
11C-MET-PET/MRI: a feasibility study[J]. Eur J Nucl Med Mol [40] EVANGELISTA L, ZATTONI F, CASSARINO G, et al. PET/MRI in
Imaging, 2017, 44(8): 1285-1295. DOI: 10.1007/s00259-017-3661-0. prostate cancer: a systematic review and meta-analysis[J]. Eur J Nucl Med
[20] FLYGARE L, ERDOGAN S T, SÖDERKVIST K. PET/MR versus Mol Imaging, 2021, 48(3): 859-873. DOI: 10.1007/s00259-020-05025-0.
PET/CT for locoregional staging of oropharyngeal squamous cell [41] KANE C J, AMLING C L, JOHNSTONE P A, et al. Limited value of
cancer[J]. Acta Radiol, 2023, 64(5): 1865-1872. DOI: 10.1177/0284185 bone scintigraphy and computed tomography in assessing biochemical
1221140668. failure after radical prostatectomy[J]. Urology, 2003, 61(3): 607-611.
[21] VALDEC S, BOSSHARD F A, HÜLLNER M, et al. Value of DOI: 10.1016/s0090-4295(02)02411-1.
FDG-PET/MR in oral focus assessment in head and neck cancer [42] CARRIE C, HASBINI A, LAROCHE G D, et al. Salvage radiotherapy
patients-a feasibility study[J/OL]. Front Med, 2022, 9: 809323 with or without short-term hormone therapy for rising prostate-specific
[2024-03-05]. https://pubmed.ncbi.nlm.nih.gov/35386916/. DOI: 10.3389/ antigen concentration after radical prostatectomy (GETUG-AFU 16): a
fmed.2022.809323. randomised, multicentre, open-label phase 3 trial[J]. Lancet Oncol,
[22] SAMOLYK-KOGACZEWSKA N, SIERKO E, DZIEMIANCZYK- 2016, 17(6): 747-756. DOI: 10.1016/S1470-2045(16)00111-X.
PAKIELA D, et al. Usefulness of hybrid PET/MRI in clinical [43] STEPHENSON A J, SHARIAT S F, ZELEFSKY M J, et al. Salvage
evaluation of head and neck cancer patients[J/OL]. Cancers, 2020, radiotherapy for recurrent prostate cancer after radical prostatectomy[J].
12(2): 511 [2024-03-05]. https://pubmed.ncbi.nlm.nih.gov/32098356/. JAMA, 2004, 291(11): 1325-1332. DOI: 10.1001/jama.291.11.1325.
DOI: 10.3390/cancers12020511. [44] AFSHAR-OROMIEH A, ZECHMANN C M, MALCHER A, et al.
[23] OHLIGER M A, HOPE T A, CHAPMAN J S, et al. PET/MR imaging Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and
in gynecologic oncology[J]. Magn Reson Imaging Clin N Am, 2017, (18)F-choline-based PET/CT for the diagnosis of recurrent prostate
25(3): 667-684. DOI: 10.1016/j.mric.2017.03.012. cancer[J]. Eur J Nucl Med Mol Imaging, 2014, 41(1): 11-20. DOI:
[24] XU C, DU S Y, ZHANG S Y, et al. Value of integrated PET-IVIM MR 10.1007/s00259-013-2525-5.
in assessing metastases in hypermetabolic pelvic lymph nodes in [45] RICE S L, FRIEDMAN K P. Clinical PET-MR imaging in breast
cervical cancer: a multi-parameter study[J]. Eur Radiol, 2020, 30(5): cancer and lung cancer[J]. PET Clin, 2016, 11(4): 387-402. DOI:
2483-2492. DOI: 10.1007/s00330-019-06611-z. 10.1016/j.cpet.2016.05.008.
[25] STEINER A, NARVA S, RINTA-KIIKKA I, et al. Diagnostic [46] FOWLER A M, STRIGEL R M. Clinical advances in PET-MRI for
18
efficiency of whole-body F-FDG PET/MRI, MRI alone, and SUV breast cancer[J/OL]. Lancet Oncol, 2022, 23(1): e32-e43 [2024-03-05].
and ADC values in staging of primary uterine cervical cancer[J/OL]. https://pubmed.ncbi.nlm.nih.gov/34973230/. DOI: 10.1016/S1470-2045(21)
Cancer Imaging, 2021, 21(1): 16 [2024-03-05]. https://pubmed. ncbi. 00577-5.
nlm.nih.gov/33482909/. DOI: 10.1186/s40644-020-00372-5. [47] BRUCKMANN N M, MORAWITZ J, FENDLER W P, et al. A role of
[26] RAHMAN W T, WALE D J, VIGLIANTI B L, et al. The impact of PET/MR in breast cancer?[J]. Semin Nucl Med, 2022, 52(5): 611-618.
18
infection and inflammation in oncologic F-FDG PET/CT imaging[J/OL]. DOI: 10.1053/j.semnuclmed.2022.01.003.
Biomedecine Pharmacother, 2019, 117: 109168 [2024-03-05]. https:// [48] SOTOUDEH H, SHARMA A, FOWLER K J, et al. Clinical
pubmed.ncbi.nlm.nih.gov/31334700/. DOI: 10.1016/j.biopha.2019.109168.
[27] GAO S, DU S Y, LU Z M, et al. Multiparametric PET/MR (PET and application of PET/MRI in oncology[J]. J Magn Reson Imaging, 2016,
44(2): 265-276. DOI: 10.1002/jmri.25161.
MR-IVIM) for the evaluation of early treatment response and [49] FRAUM T J, LUDWIG D R, HOPE T A, et al. PET/MRI for
prediction of tumor recurrence in patients with locally advanced gastrointestinal imaging: current clinical status and future prospects[J].
cervical cancer[J]. Eur Radiol, 2020, 30(2): 1191-1201. DOI: 10.1007/
s00330-019-06428-w. Gastroenterol Clin North Am, 2018, 47(3): 691-714. DOI: 10.1016/j.
[28] XU C, SUN H Z, DU S Y, et al. Early treatment response of patients gtc.2018.04.011.
undergoing concurrent chemoradiotherapy for cervical cancer: an [50] MIRSHAHVALAD S A, HINZPETER R, KOHAN A, et al. Diagnostic
18
evaluation of integrated multi-parameter PET-IVIM MR[J/OL]. Eur J performance of [ F]-FDG PET/MR in evaluating colorectal cancer: a
Radiol, 2019, 117: 1-8 [2024-03-05]. https://pubmed.ncbi.nlm.nih.gov/ systematic review and meta-analysis[J]. Eur J Nucl Med Mol Imaging,
31307633/. DOI: 10.1016/j.ejrad.2019.05.012. 2022, 49(12): 4205-4217. DOI: 10.1007/s00259-022-05871-0.
[29] NIE J, ZHANG J, GAO J S, et al. Diagnostic role of 18F-FDG PET/ [51] ÇELEBI F, YAGHOUTI K, CINDIL E, et al. The role of 18F-FDG
MRI in patients with gynecological malignancies of the pelvis: a PET/MRI in the assessment of primary intrahepatic neoplasms[J].
systematic review and meta-analysis[J/OL]. PLoS One, 2017, 12(5): Acad Radiol, 2021, 28(2): 189-198. DOI: 10.1016/j.acra.2020.01.026.
e0175401 [2024-03-05]. https://pubmed. ncbi. nlm. nih. gov/28481958/. [52] GUNIGANTI P, KIERANS A S. PET/MRI of the hepatobiliary system:
DOI: 10.1371/journal.pone.0175401. review of techniques and applications[J/OL]. Clin Imaging, 2021, 71:
[30] MCGETTIGAN M, ZULFIQAR M, SHETTY A S. Imaging of vaginal 160-169 [2024-03-05]. https://pubmed.ncbi.nlm.nih.gov/33285404/. DOI:
and vulvar malignancy[J]. Radiol Clin North Am, 2023, 61(4): 651-670. 10.1016/j.clinimag.2020.10.056.
DOI: 10.1016/j.rcl.2023.02.010. [53] JOO I, LEE J M, LEE D H, et al. Preoperative assessment of pancreatic
[31] VIRARKAR M, GANESHAN D, GULATI A T, et al. Diagnostic cancer with FDG PET/MR imaging versus FDG PET/CT plus
performance of PET/CT and PET/MR in the management of ovarian contrast-enhanced multidetector ct: a prospective preliminary study[J].
carcinoma-aliterature review[J]. Abdom Radiol, 2021, 46(6): 2323-2349. Radiology, 2017, 282(1): 149-159. DOI: 10.1148/radiol.2016152798.
DOI: 10.1007/s00261-020-02847-2. [54] 李旭东, 林晓珠 . PET/MRI在胰腺肿瘤中的应用[J]. 国际医学放射学
[32] JÓNSDÓTTIR B, MARCICKIEWICZ J, BORGFELDT C, et al. 杂志, 2018, 41(1): 59-61, 84. DOI: 10.19300/j.2018.Z5124.
Preoperative and intraoperative assessment of myometrial invasion in LI X D, LIN X Z. The application of PET/MRI in pancreatic neoplasms[J].
endometrial cancer-a Swedish Gynecologic Cancer Group (SweGCG) Int J Med Radiol, 2018, 41(1): 59-61, 84. DOI: 10.19300/j.2018.Z5124.
study[J]. Acta Obstet Gynecol Scand, 2021, 100(8): 1526-1533. DOI: [55] SCHMIDKONZ C, ELLMANN S, RITT P, et al. Hybrid imaging
10.1111/aogs.14146. (PET-computed tomography/PET-MR imaging) of bone metastases[J].
[33] SHREVE P D, ANZAI Y, WAHL R L. Pitfalls in oncologic diagnosis PET Clin, 2019, 14(1): 121-133. DOI: 10.1016/j.cpet.2018.08.003.
with FDG PET imaging: physiologic and benign variants[J]. Radiographics, [56] MANHAS N S, SALEHI S, JOYCE P, et al. PET/computed
1999, 19(1): 61-77. DOI: 10.1148/radiographics.19.1.g99ja0761. tomography scans and PET/MR imaging in the diagnosis and
[34] KUNZ G, LEYENDECKER G. Uterine peristaltic activity during the management of musculoskeletal diseases[J]. PET Clin, 2020, 15(4):
menstrual cycle: characterization, regulation, function and dysfunction[J]. 535-545. DOI: 10.1016/j.cpet.2020.06.005.
Reprod Biomed Online, 2002, 4(Suppl 3): 5-9. DOI: 10.1016/s1472-6483(12)
60108-4. （下转第26页）
·14 · https://www.chinesemri.com